Efficacy of Rifaximin-Î± vs Dietary Fiber on the Evolution of Uncomplicated Colonic Diverticular Disease

Copaci, I.; Constantinescu, Gabriel; Mihaila, Mariana; Micu, L.; Franculescu-Bertea, Andreea

doi:10.21614/sgo-24-5-233

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results in terms of symptom relief were reported by other smaller studies [ 112 , 113 , 114 , 115 ], with evidence of benefit persistence over a longer period, as demonstrated by a retrospective study that analyzed patients for an 8-year follow-up [ 113 ]. As a chronic relapsing disease, SUDD requires cyclical treatment (7–10 days per month) as recommended by various guidelines [ 106 , 112 , 116 ]. From these data, it emerges that a periodic and scheduled treatment is more effective than an “on demand” one, performed only when symptoms occur, both for symptom control and for preventing long-term complications.…”

Section: Rifaximinmentioning

confidence: 99%

Diverticular Disease and Rifaximin: An Evidence-Based Review

et al. 2023

View full text Add to dashboard Cite

There have been considerable advances in the treatment of diverticular disease in recent years. Antibiotics are frequently used to treat symptoms and prevent complications. Rifaximin, a non-absorbable antibiotic, is a common therapeutic choice for symptomatic diverticular disease in various countries, including Italy. Because of its low systemic absorption and high concentration in stools, it is an excellent medicine for targeting the gastrointestinal tract, where it has a beneficial effect in addition to its antibacterial properties. Current evidence shows that cyclical rifaximin usage in conjunction with a high-fiber diet is safe and effective for treating symptomatic uncomplicated diverticular disease, while the cost-effectiveness of long-term treatment is unknown. The use of rifaximin to prevent recurrent diverticulitis is promising, but further studies are needed to confirm its therapeutic benefit. Unfortunately, there is no available evidence on the efficacy of rifaximin treatment for acute uncomplicated diverticulitis.

show abstract

Section: Rifaximinmentioning

confidence: 99%

Diverticular Disease and Rifaximin: An Evidence-Based Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Эффективность циклического применения рифаксимина (7-10 дней ежемесячно) у пациентов с СНДБ подтверждена в большом количестве клинических исследований [87,88]. В двой ном слепом плацебо-контролируемом рандомизированном клиническом исследовании [81], а также в открытых исследованиях [89] и по результатам мета-анализов [90] [88,89]. Таким образом, комбинация рифаксимина, назначаемого в течение 7-10 дней ежемесячно, и растворимых пищевых волокон, является высоко эффективной при лечении СНДБ, что также было подтверждено в многочисленных клинических исследованиях [87,88].…”

Section: комментарий: обоснование применения плохо всасываемых антиби...unclassified

Colonic diverticular disease: clinical presentation, diagnosis, treatment, and prevention Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North- West Society of Gastroenterologists and Hepatologists

Drapkina

Лазебник

Бакулин

et al. 2023

jour

View full text Add to dashboard Cite

Clinical guidelines are intended for gastroenterologists, internists, and general practitioners and focus primarily on the management of patients with symptomatic uncomplicated diverticular disease, as well as on the primary and secondary prevention of acute diverticulitis and other complications of diverticular disease. Clinical guidelines were developed by the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientifi c Society of Russia, and the North-West Society of Gastroenterologists and Hepatologists. One of the reasons for creating new clinical guidelines is that the current guidelines on diverticular disease (2021) pay much more attention to complications of diverticular disease and surgical treatment of acute and chronic complications of the disease.

show abstract

“…Es fand eine fragliche Randomisierung statt, die Einschlusskriterien verlangten keine Bildgebung. Nach 3 Monaten verbesserte sich ein globaler Symptomenkomplex in beiden Guppen, eine Statistik zum interinterventionellen Unterschied wurde nicht angegeben [453]. Die Datenlage für die Akutbehandlung der unkomplizierten Divertikelkrankheit ist mithin so gering und uneinheitlich, dass eine Evidenz-Empfehlung nicht ausgesprochen werden kann.…”

Section: Kommentarunclassified